成大生物：聘任李业基为公司董事会秘书

Group 1 - The company announced that Mr. Cui Jianwei will no longer serve as the Secretary of the Board due to adjustments in work responsibilities, but will continue in his roles as Director, Deputy General Manager, and Chief Financial Officer [2] - Mr. Li Yeji has been appointed as the new Secretary of the Board following the nomination by the Chairman and approval by the Board Nomination Committee [2] - The company's revenue composition for the year 2024 is entirely from biopharmaceuticals, accounting for 100.0% of the total revenue [3]